December 14, 2018
VIDAC PHARMA ANNOUNCES PUBLICATION OF A PEER REVIEWED ARTICLE ON VDA-1102 MECHANISM OF ACTION
Jerusalem, Israel, December 16 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, announce the publication of its latest article in the prestigious Journal of Investigative Dermatology (2018, vol 138:2635-2643),…
November 04, 2018
VIDAC PHARMA TO PRESENT A POSTER AT THE SITC 2018 MEETING
Jerusalem, Israel, November 4, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, DC. The poster…
July 10, 2018
VIDAC PHARMA ANNOUNCES INITIATION OF PHASE 2B CLINICAL TRIAL OF VDA-1102 OINTMENT IN PATIENTS WITH ACTINIC KERATOSIS
Jerusalem, Israel, July 10 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, today announced initiation of a Phase 2b clinical trial of VDA-1102 ointment to treat subjects with actinic keratosis (AK), an early…
June 20, 2018
VIDAC PHARMA TO PRESENT A POSTER AT THE EACR25 2018 MEETING
Jerusalem, Israel, June 20, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach to Target Metabolic Immuno-Oncology” at the…
Apr 04, 2018
VIDAC PHARMA TO PRESENT AN IMMUNO-METABOLISM POSTER AT THE 2018 AACR ANNUAL MEETING 2018
Jerusalem, Israel, April 4, 2018 – Vidac Pharma, a clinical stage oncology and…
Jan 23, 2018
VIDAC PHARMA TO PRESENT AT THE 2018 BIO CEO & INVESTOR CONFERENCE
Jerusalem, Israel, January 23, 2018 – Vidac Pharma, a clinical-stage oncology and…
Dec 06, 2017
VIDAC PHARMA TO PRESENT AT THE 2018 4TH ANNUAL DERMATOLOGY INNOVATION FORUM
Jerusalem, Israel, December 6, 2017 – Vidac Pharma, a clinical stage oncology and…
Oct 12, 2017
VIDAC PHARMA REPORTS POSITIVE RESULTS FROM PHASE 2A PROOF-OF-CONCEPT TRIAL OF VDA-1102 OINTMENT IN ACTINIC KERATOSIS
Vidac Pharma reports positive results from Phase 2A Proof-of-concept trial of VDA-1102…
Jan 01, 2017
VIDAC PHARMA APPOINTS CHIEF MEDICAL AND CHIEF SCIENCE OFFICERS
Jerusalem, Israel, January 1, 2017 – Vidac Pharma, a clinical-stage oncology-focused…
Dec 12, 2016
VIDAC PHARMA PHASE 2A STUDY OF VDA-1102 IN ACTINIC KERATOSIS MEETS INTERIM ANALYSIS CRITERION
Jerusalem, Israel, December 12, 2016 – Vidac Pharma, a clinical-stage oncology-focused…
Jul 29, 2016
VIDAC PHARMA ANNOUNCES THE INNITIATION OF A PHASE 2A STUDY OF VDA-1102 OINTMENT IN PATIENTS WITH ACTINIC KERATOSIS
Jerusalem, Israel, July 29, 2016 – Vidac Pharma, a clinical stage oncology focused…
Jun 30, 2016
VIDAC PHARMA COMPLETES PHASE 1A TRIAL OF VDA-1102 OINTMENT
Jerusalem, Israel, June 30, 2016 – Vidac Pharma, a clinical stage oncology focused…
Jun 29, 2016
Vidac Pharma Completes $9 Million Series A Financing I Advances Phase 2 Studies with VDA-1102 In Actinic Keratosis
Jerusalem, Israel, June 29, 2016 – Vidac Pharma, a privately-held clinical stage…
Feb 25, 2016
Vidac Pharma Initiates Phase I Clinical Trial With Its Novel VDAC/HK2 Modulator
Jerusalem, Israel, February 25, 2016 – Vidac Pharma, a clinical stage drug development…
Dec 30, 2015
Vidac Pharma Announces Filing of IND with U.S. FDA for Development of VDA-1102 for Treatment of Actinic Keratosis
Jerusalem, Israel, December 30, 2015 – Vidac Pharma, a drug discovery and development…
Oct 15, 2014
Vidac Pharma Appoints Dr. Chaim Brickman as Vice President of Clinical Affairs
Jerusalem, Israel, November 15, 2014 – Vidac Pharma, a drug discovery and development…
Aug 19, 2014
Vidac Pharma Appoints Dr. Paul Salama as Vice President of Chemistry, Manufacturing, and Control
Ness Ziona, Israel, August 19, 2014 – Vidac Pharma, a drug discovery and development…
Factsheet